Compare ACGLN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACGLN | KPTI |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Bermuda | United States |
| Employees | 5800 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 94.6M |
| IPO Year | N/A | 2013 |
| Metric | ACGLN | KPTI |
|---|---|---|
| Price | $16.99 | $7.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.17 |
| AVG Volume (30 Days) | N/A | ★ 282.6K |
| Earning Date | N/A | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $142,530,000.00 |
| Revenue This Year | N/A | $3.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $3.51 |
| 52 Week High | N/A | $12.45 |
| Indicator | ACGLN | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 68.22 |
| Support Level | $16.52 | $7.01 |
| Resistance Level | $17.13 | $7.44 |
| Average True Range (ATR) | 0.19 | 0.46 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 70.51 | 84.03 |
Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.